| 영문 | liver function tests | 한글 | 간기능검사 |
|---|---|---|---|
| 설명 | 혈액검사중 가장 많이 쓰이는 검사법으로 다음 7가지를 검사하게 된다. 혈청콜레스테롤, 총단백질, 알부민, 빌리루빈, GOT/GPT 효소, 알칼리인산분해효소(alkaline phophatase) 등을 검사하게 되는 데 각 검사치에는 모두 의미가 있으며, 이 검사 하나로 간기능의 전반적인 상태에 대해서 알아볼 수 있다. |
||
| 영문 | pulmonary function tests | 한글 | 폐기능 검사 |
|---|---|---|---|
| 설명 | 여러 가지 기구를 이용해 폐용적 및 허파의 확산능을 알아보는 검사로 말 그대로 허파의 기능을 측정하는 검사이다. |
||
| HCG, hCG | Human Chorionic Gonadotropin; 사람융모성성선자극호르몬 1. Placental Glycoprotein Hormone &nbs... |
|---|---|
| COG | center of gravity; cognitive function tests |
| ICU | infant care unit; immunologic contact urticaria; intensive care unit; intermediate care unit |
| OILD | occupational immunologic lung disease |
| RALT | routine admission laboratory tests |
| BPT | Bronchial provocation tests |
|---|---|
| CPT | Conjunctival provocation tests |
| IVGTT | I.v. glucose tolerance tests |
| IFT | Immunofluorescence tests |
| IDT | Intradermal tests |
| cytotoxicity tests, immunologic | The demonstration of the cytotoxic effect on a target cell of a lymphocyte, a mediator released by a sensitised lymphocyte, an antibody, or complement. (12 Dec 1998) |
|---|
| cytotoxicity, immunologic | The phenomenon of target cell destruction by immunologically active effector cells. It may be brought about directly by sensitised T-lymphocytes or by lymphoid or myeloid "killer" cells, or it may be mediated by cytotoxic antibody, cytotoxic factor released by lymphoid cells, or complement. (12 Dec 1998) |
|---|---|
| immunologic tests | Diagnostic techniques involving the demonstration or measurement of an immune response, including antibody production or assay, antigen-antibody reactions, serologic cross-reactivity, delayed hypersensitivity reactions, or heterogenetic responses. (12 Dec 1998) |
| antibody-dependent cell cytotoxicity | The phenomenon of antibody-mediated target cell destruction by non-sensitised effector cells. The identity of the target cell varies, but it must possess surface IgG whose fc portion is intact. The effector cell is a "killer" cell possessing fc receptors. It may be a lymphocyte lacking conventional b- or T-cell markers, or a monocyte, macrophage, or polynuclear leukocyte, depending on the identity of the target cell. The reaction is complement-independent. (12 Dec 1998) |
| cytotoxicity | The quality or state of being cytotoxic. Antibody-dependent cell-mediated cytotoxicity (ADCC), a form of lymphocyte-mediated cytotoxicity that functions only if antibodies are bound to the target cell. Lymphocyte-mediated cytotoxicity, the toxic or lytic activity of T-lymphocytes, which may or may not be mediated by antibodies. Cytotoxic T lymphocytes may cause lysis of cells by production of cytolytic proteins such as perforin. B-cells may cause lysis of cells by antibody-complement binding to a target cell. Natural killer cells are cytotoxic without prior sensitization. Toxicity by lymphocytes may also be mediated by antibodies; there are three kinds of cytotoxic T-lymphocytes: those that are antigen-specific as a result of previous allergization (immunization), killer cells, and natural killer cells. See: antibody-dependent cell-mediated cytotoxicity. (05 Mar 2000) |
| adjuvants, immunologic | Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (freund's adjuvant, bcg, corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity. (12 Dec 1998) |
| receptors, immunologic | Cell surface molecules on cells of the immune system that specifically bind surface molecules or messenger molecules and trigger changes in the behaviour of cells. Although these receptors were first identified in the immune system, many have important functions elsewhere. (12 Dec 1998) |
| graft enhancement, immunologic | The induction of prolonged survival and growth of allografts of either tumours or normal tissues which would ordinarily be rejected. It may be induced passively by introducing graft-specific antibodies from previously immunised donors, which bind to the graft's surface antigens, masking them from recognition by T-cells; or actively by prior immunization of the recipient with graft antigens which evoke specific antibodies and form antigen-antibody complexes which bind to the antigen receptor sites of the T-cells and block their cytotoxic activity. (12 Dec 1998) |
| monitoring, immunologic | Testing of immune status in the diagnosis and therapy of cancer, immunoproliferative and immunodeficiency disorders, and autoimmune abnormalities. Changes in immune parameters are of special significance before, during and following organ transplantation. Strategies include measurement of tumour antigen and other markers (often by radioimmunoassay), studies of cellular or humoral immunity in cancer aetiology, immunotherapy trials, etc. (12 Dec 1998) |
| contraception, immunologic | Contraceptive methods utilizing immunologic processes. (12 Dec 1998) |
| suppressor factors, immunologic | Proteins, protein complexes, or glycoproteins secreted by suppressor T-cells that inhibit either subsequent T-cells, B-cells, or other immunologic phenomena. Some of these factors have both histocompatibility (I-j) and antigen-specific domains which may be linked by disulfide bridges. They can be elicited by haptens or other antigens and may be mass-produced by hybridomas or monoclones in the laboratory. (12 Dec 1998) |
| desensitization, immunologic | Immunosuppression by the administration of increasing doses of antigen. Though the exact mechanism is not clear, the therapy results in an increase in serum levels of allergen-specific IgG, suppression of specific IgE, and an increase in suppressor T-cell activity. (12 Dec 1998) |
| dose-response relationship, immunologic | A specific immune response elicited by a specific dose of an immunologically active substance or cell in an organism, tissue, or cell. (12 Dec 1998) |
| immunologic | <immunology> Pertaining to immunology. (18 Nov 1997) |
| immunologic and biological factors | A collective grouping for biologically active substances that play a role in the functioning of the immune system and those that show biological or physiological activity. (12 Dec 1998) |
| immunologic capping | The process by which lymphoid cell surface immunoglobulin receptors, when exposed to bivalent anti-ig antibodies, collect in patches and form a cap at one pole of the cell. The caps may then be endocytosed or shed into the environment in the form of antigen-antibody complexes. Capping has also been induced by lectins and antigens. (12 Dec 1998) |
Synonyms : Anti Human Globulin Complement Dependent Cytotoxicity Tests, Anti-Human Globulin Complement-Dependent Cytotoxicity Test, Antiglobulin-Augmented Lymphocytotoxicity Test, Antiglobulin-Augmented Lymphocytotoxicity Tests, Cytotoxicity Test, Immunologic
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|